The Pharmacy Is 1.4 Miles Away. The Methadone Clinic Is 12. Congress Just Asked Why.

Lydia has been on methadone for three years. In that time, it has done what it was supposed to do: it has kept her off fentanyl, kept her employed, kept her present for her kids in ways she had not been able to manage during the years she was using. She is, by any clinical measure, thriving. She is also driving 23 miles each way to a clinic six mornings a week, leaving her apartment before 6 a.m. to be back in time for a 9 o’clock shift she cannot afford to lose.

The pharmacy that fills her blood pressure medication is four blocks from her front door.

This is not a story about Lydia specifically — she asked not to be named, and her story is not unusual. It is, in fact, the unremarkable daily structure of medication-assisted treatment for opioid use disorder in the United States in 2026: the most effective pharmacological intervention we have for a condition killing roughly 190 Americans a day requires, for hundreds of thousands of people, a daily trip to a specialized clinic that most communities don’t have and most patients can barely reach.

America decided methadone was too dangerous to leave the clinic. It built a 50-year system where getting the medication means building your life around the commute to get it — and for rural patients, that commute averages 49 miles each way.

On June 25, Senators Ed Markey (D-MA) and Rand Paul (R-KY) reintroduced the Modernizing Opioid Treatment Access Act 2.0 — a bill that would, for the first time since 1974, let board-certified addiction physicians prescribe methadone directly and let pharmacies dispense it. If it passes, Lydia could pick up her methadone where she picks up everything else that keeps her healthy. If it stalls, she keeps driving.

---

The bill: what it would actually change

The current system is simpler to understand if you look at what methadone is not. Methadone is not like buprenorphine — which any credentialed physician can prescribe and any pharmacy can fill, since the DATA 2000 waiver requirement was eliminated in late 2022. Methadone for opioid use disorder is available only through federally certified opioid treatment programs (OTPs), of which there are roughly 2,000 nationwide for an estimated 5 million people with OUD. Fewer than 20 percent of people with OUD receive any form of medication treatment at all.

The Markey-Paul bill — which STAT News reported on June 25 and which passed the Senate HELP Committee in December 2023 before dying without a floor vote — would give the Department of Health and Human Services authority to designate additional prescribers without requiring new legislation. Board-certified addiction medicine physicians and other qualifying providers could prescribe methadone for OUD the way they prescribe any other controlled medication. Pharmacies could fill those prescriptions. OTPs would remain; they would not be eliminated. But the clinic would no longer be the only door.

The American Society of Addiction Medicine backs the bill. The Drug Policy Alliance applauded its reintroduction. The opposition, notably, includes some private equity-owned clinic chains — an alignment of interests that tells you something about what the current system has become.

---

A 50-year decision we made in 1974 and never revisited

Patients average 4.5 times farther to the nearest OTP than to the nearest pharmacy. In rural areas, a 2021 analysis in Drug and Alcohol Dependence found the gap is starker: the nearest OTP sits an average of 49 miles from rural patients, compared to 5 miles for urban ones. The distance kills people — the same analysis found that geographic inaccessibility to OTPs is independently associated with higher overdose mortality, controlling for other factors. The commute isn’t just inconvenient. It is, for some people, the difference between staying in treatment and dying.

The distance kills people — the same analysis found that geographic inaccessibility to OTPs is independently associated with higher overdose mortality, controlling for other factors.

The federal decision to lock methadone behind registered clinics wasn’t inevitable. It was a choice made in the early 1970s under the Nixon administration and formalized in 1974 regulations — the same era that gave us the Controlled Substances Act, the Drug Enforcement Administration, and a federal policy framework built primarily around the concept of diversion risk.

The architects of the OTP system believed that supervised daily dosing, in a clinical setting, would prevent methadone from being sold on the street. What they did not model for — or did not weigh — was what daily supervised dosing would mean for someone who worked an early shift, who lived in a rural county without reliable transit, who had children to get to school, or who simply couldn’t rebuild a life around a 6 a.m. clinic attendance requirement. The structure was designed to manage the risk of the medication. It was not designed around the lives of the patients receiving it.

That structure has survived Nixon, Ford, Carter, Reagan, Bush, Clinton, Bush, Obama, Trump, Biden, and now Trump again — 50 years during which methadone’s evidence base grew dramatically and the structural barriers to accessing it remained almost unchanged. Even the pandemic’s telehealth flexibilities, which allowed some patients to receive more take-home doses, left the fundamental question of who can prescribe untouched.

We have done this before, and we know how it ends. In the 1980s, when AIDS was spreading fastest among people who injected drugs, Congress banned federal funding for syringe exchanges on the grounds that providing clean needles would “send the wrong message.” The ban lasted 21 years. We counted the dead in the meantime. The methadone clinic system is not identical to the syringe exchange ban, but the logic underlying both is the same: the design of care around the management of optics rather than the survival of patients.

---

What the commute actually costs

If you have ever set your alarm for 5:30 a.m. on a Tuesday to make it to the clinic before work, you already know what the word “compliance” costs in units beyond time. The daily clinic visit in early methadone treatment is not just logistically burdensome — the psychological architecture of it is built around supervised trust, and it communicates something to the person receiving treatment whether the staff intend it to or not.

You check in. You are observed drinking your dose. If you submit a clean urine sample and attend consistently, you earn take-home privileges over weeks and months. Miss a day — for any reason, including car trouble, a sick child, a court date, a shift that started early — and the clock on those take-home privileges can reset. The structure says, implicitly and sometimes explicitly: we don’t trust you with this medication yet. We’ll let you know when you’ve earned it.

For someone rebuilding a sense of competence and agency in early recovery, the experience of daily observation matters. Research on therapeutic alliance and treatment retention is consistent: the relationship between a patient and their treatment environment is not incidental to outcomes; it is constitutive of them. A treatment model that requires daily proof of sobriety before you can leave with your medication is not the same as a treatment model that trusts you with a monthly prescription the way it trusts you with blood pressure medication.

This is not an argument against OTPs. Many OTP staff provide extraordinary care and the clinic setting can be a real source of community and stability for some patients. This is an argument about what we are requiring of patients who do not have access to an OTP at reasonable distance, or for whom the daily trip is incompatible with maintaining the employment, custody, and daily structure that treatment is supposed to enable. We are asking people to do the hardest work of their lives while building that work around a 23-mile commute.

We are asking people to do the hardest work of their lives while building that work around a 23-mile commute.

---

What providers can do now, while the bill finds a floor vote

The Markey-Paul bill passed committee once before and died without a vote. Its current prospects depend on the Senate calendar and whether bipartisan momentum on opioid treatment translates to floor time. That is not a given.

In the meantime, people with OUD who cannot access an OTP are not without options — but those options are narrower, and providers should know them precisely and not approximately. Buprenorphine — the other first-line MOUD — can be prescribed by any qualifying provider and dispensed at any pharmacy, and for many patients it is highly effective. It does not require daily clinic attendance. For patients who are on buprenorphine and stable but who would clinically benefit from methadone — higher tolerant individuals, those with certain comorbidities — the barrier is meaningful and not a pharmaceutical equivalence.

Case managers: document your patients’ commute burden to the OTP. That data matters for advocacy. If you have patients who are missing doses because of transportation gaps, that is a clinical and policy problem, and it belongs in the record.

Providers: contact your senators about this bill. The bill has bipartisan sponsorship, ASAM support, and a history of clearing committee. What it has not had is floor time. The difference between a bill that dies in committee and one that becomes law is often a call from a constituent who can explain why the policy gap kills people.

---

The road and the door

Lydia does not need to be told that methadone works. She knows it the way anyone knows something that has kept them alive. What she also knows, on those mornings when she’s scraping ice off the windshield at 5:45 a.m. in January, is that the system she depends on was not designed with her life in mind. It was designed with its own liability in mind.

The Markey-Paul bill will not pass this month. It may not pass this session. But the reintroduction of a bipartisan bill with this much institutional backing marks the first real chance in a generation to ask whether a regulation made under Nixon in 1974 should still govern how 5 million people with OUD access their treatment in 2026. The answer, finally, seems like it might be no.

Buprenorphine is accessible today. For patients who cannot reach an OTP, it is a legitimate first-line option with a robust evidence base. Ask the question. Make the referral. Lydia didn’t have that conversation for two years because nobody offered it; she ended up on methadone through an OTP because it was the only door her first provider knew how to open.

There are more doors now. Make sure your patients know where they are.